Requests that the FDA take administrative action to improve the safety of discontinuing Cymbalta (duloxetine) and generic equivalents by requiring standardized tapering formulations, updated labeling, and patient access protections
🏛 Food and Drug Administration (FDA)FDA-2026-P-1831
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.